Hernández CC, Carnot UJ, Muñío PJ, Cepero LK, Pardo RI

Language: Spanish
References: 0
Page: 69-74
PDF size: 55.34 Kb.

ABSTRACT

Allogeneic stem cell transplantation is a potentially curative treatment for many patients affected by haematological disorders, whether malignant or nonmalignant. In spite of this, finding the best donor possible at the appropriate time to carry out the transplantation has gradually become one of the most difficult logistic problems to be solved for this procedure. It is in this context where the application of the procedure is inserted with the use of haploidentical donors. The most forceful way to tackle this type of transplant today is the one described by researchers at Johns Hopkins University in Baltimore, USA, where a nonmyeloablative conditioning treatment and a prophylaxis of graft-versus-host disease (GVHD) are used, including the application of high doses of cyclophosphamide on the days +3 and +4. Results are very encouraging in terms of mortality not related to relapse, the occurrence of GVHD, as well as the probability of relapse, progression-free survival and overall survival. Therefore, its implementation is allowing access to many potential donors. Its current profile in terms of therapeutic results, accessibility, economic costs and potential benefits to a greater number of patients makes it a viable and significant alternative for a country with characteristics like ours.